• 생명과학회지
• /
• 제17권2호통권82호
• /
• pp.235-240
• /
• 2007

본 연구는 Affymetrix Arabidopsis DNA chip을 이용하여 비 병원성 인자인 AvrRpt2 단백질에 의해서 특이적으로 전사 과정이 조절되는 애기장대 유전자들을 분리하고 병 저항성 방어체계와 관련한 이들 유전자들의 기능 분석을 시도하였다. 그 중에서 먼저 식물 호르몬인 ethylene의 신호 조절에 관여하는 ERFs (ethylene-responsive element binding factors) 전사조절 유전자 family 중에서 Bla subfamily 그룹으로 알려져 있는 AtERF11 유전자의 병 저항성 관련 기능을 규명하였다. 저항성 유전자 RPS2가 없는 경우에는 비 병원성 인자인 AvrRpt2 단백질은 기주 식물체내의 기초 병저항성을 감소시키고 병원성 세균의 증식을 향상시켜서 병증을 증대시키는 effector로 작용한다는 기존의 연구결과와 유사하게, 저항성 유전자 RPS2가 없는 조건에서 AtERF11 유전자의 발현이 AvrRpt2 단백질의 작용에 의해서 특이적으로 감소되는 것을 확인하였다. 이러한 결과를 바탕으로 AtERF11 유전자는 식물체의 병 저항성 방어기작에 있어서 positive regulator로서 작용하기 때문에 effector로 작용하는 AvrRpt2 단백질에 의해서 조절되는 것으로 추측하였다. 본 가설을 증명하기 위해 AtERF11의 발현을 증폭시킨 애기장대 형질전화체를 제작하고 P. syringae pv. tomato DC 3000에 대한 병저항성을 실험하였다. AtERF11 유전자가 대량 발현하는 형질전화 된 애기장대에서는 야생종에 비해 대략 100배 이상 세균의 증식이 억제되는 강력한 병저항성을 가진다는 것을 검증하였다.

• 생명과학회지
• /
• 제21권2호
• /
• pp.227-234
• /
• 2011

Pseudomonas syringae pv. tabaci는 숙주인 담배에 감염하여 들불병(wild fire)을 일으키는 식물 병원성 세균이다. 이 세균의 pathogenicity island (PAI)는 Type III secretion system 및 병원성 유전자들을 암호화하고 있으며, 병원성 조절에 있어 핵심적인 역할을 한다. 최근 식물 병원성 세균인 Ralstonia solanacearum에서 식물 세포 접촉을 매개로 하여 hrp gene cluster를 양성조절하는 PrhA (plant regulator of hrp) receptor가 발견되었다. 본 연구에서는 P. syringae에서 식물세포에 의해 hrp 유전자가 유도되는지 확인하기 위해, prhA 유사체를 동정하고 PrhA 결실돌연변이주(BL11)를 구축하였다. BL11은 숙주 감염 실험에서 병원성이 현저히 감소하였고, 식물 세포현탁액에서 hrpA 유전자의 발현수준이 hrp 유도배지에서 보다 3배 더 높게 나타났다. 이러한 결과들을 근거로 PrhA가 식물세포접촉에 의한 조절에 중요한 역할을 한다는 것을 확인하였으며, hrpA-gfp reporter fusion을 사용하여 이를 다시 검증하였다.

• Journal of Chest Surgery
• /
• 제19권1호
• /
• pp.35-42
• /
• 1986

Prevention of thrombombolism after rosthetic cardiac valve replacement is essential for the patients. About 90% of patients are free of major and minor thromboembolic complications 5 year after replacement of cardiac valves with prosthetic devices when they are under control of anticoagulant therapy. Ticlopidine is a drug that alter platelet function to have an antithrombotic effect. It is an antiaggregating agent which inhibits primary platelet function to have an antithrombotic effect. It is an antiaggregating agent which inhibits primary platelet aggregation induced by ADP and increases the production of prostaglandin $D_{2}$. Aspirin in small doses inhibits platelet synthesis of prostaglandins by irreversibly blocking the enzyme cyclo-oxygenase. Platelet secretion and aggregation are impaired with Ticlopidine and Aspirin. the thromboembolic event sof 54 patient s who were treated with Ticlopidine and Aspirin after cardiac valve replacement were evaluated and compared with that of 79 patients who were treated with Wafarin and Aspirin after the same type of operation. The follow-up period ranged from 4 to 110 months (mean of 48 months). there were 11 major thromboembolic episodes including three deaths in the warfarin goup during mean follow-up period of 56 months. two cases of CVA and one hemoarthrosis were noted due to overdose of Warfarin. Inticlopidine group, there was only one fatal thromboembolic epdisode three month after mitral valve replacement during mean follow-up period of 18 months. Two episodes of hypermenorrhea resulting anemia ere noted in the ticlopidine group. We measured the parameters of platelet function in aggreagation curve of platelet with platelet aggregometer (chrono-log Aggregometer, Model No. 430) Aggregation test was performed with three final concentrations of epinephrine in 10 uM/L, ADP in 5uM/L. 28 patients with prosthetic cardiac valves and 35 healthy volunteers were subgrouped as follows to analyze the effect of antithrombotic drugs used. Group I ; 11 patients treated with 250-500 mg of ticlopidine and 0.5gm of Aspirin as a daily single dose after cardiac valve replacement (14 St. Jude Medical and 1 Carpentier-Edwards, 9 patients with atrial fibrillation among them) Group II ; 10 patients treated with 3-5 mg of Warfarin and 0.75 gm of Aspirin daily to prolong prothrombin time around 20 seconds for more than 6 months and single Aspirin dose was maintained afterward as a life-long regimes(3 St. Jude Medical, 1 Hall-Kaster and 7 Carpentier-Edwards valve, 9 patients in atrial fibrilation). Group III ; 7 patients who quit anticoagulant treatment (Warfarin + Aspirin) 6-12 months after the regime as group II (3 St. Jude Medical. 1 bjork-Shiley, 1 Hall-Kaster, 3 Carpentier-Edwards valve, 2 of them are with atrial fibrillation). Group IV ; 35 healthy vounteers (28 males and 7 females). The following results were obtained. 1. The mean maximal platelet aggregability in Group I induced by 10uM/L epinephrine was 15.6%, and 17.5 and 18.7% in BM in proportion to the induction by 5 and 10 uM/L ADP. 2. The mean maximal platelet aggregability in Group II induced by 10uM/L epinephrine was 16.5%, and 27.4 and 44.7% in BM in proportion to the induction by 5 and 10uM/L ADP. 3. The mean maximal platelet aggregability in group III induced by 10uM/L epinephrine was 65%, and 56.5 and 51.8% in BM in proportion to the induction by 5 and 10 uM/L ADP. 4. The mean maximal platelet aggregability in the normal subjects induced by 10 uM/L epinephrine was 64%, and 65 and 69% in Bm inproportion to the induction by 5 and 10 uM/L ADP. 5. Reversible change of platelet aggregation curve induced by 5 and 10uM/L was noted all of the patients in Group I. conclusion : Ticlopidine is an antiaggregating agent which inhibits primary platelet aggregation induced by ADP, and increases the production of prostaglandin $D_{2}$. Ticlopidine and Aspirin produced a significant inhibition of platelet in the presence of ADP and epinephrine in our study. Acccording to our brief experience, 250 mg of ticlopidine and low dose of Aspirin resulted synergistic superior effect to each drug alone in prevention of thromboembolism after prosthetic cardiac valve replacement.